TEM · Tempus AI, Inc.

Current Thesis

Tempus AI's proposed Personalis acquisition supports a cancer-vaccine sequencing recovery thesis; a daily close above the 2026-08-21 reference close of $72.69 would confirm the price case, while a weekly close below $58 would invalidate it. The underlying commercial inference remains that Merck and Moderna's 2026-08-19 INTerpath-001 trial success creates demand for sequencing and molecular residual disease (MRD) testing. Their topline announcement, as described in the September 5 published research, did not establish commercial diagnostic revenue for Tempus.

The refresh weakens the price case: the market's September 11 close was $59.01, versus $64.62 on September 4, despite UBS initiating at Neutral with a $70 analyst target on September 9, according to Benzinga. The narrative is saturated — an inference from the August 31–September 9 coverage cluster and weaker subsequent reference closes, rather than a measurement of investor ownership. A recovery above $72.69 accompanied by disclosed commercial demand would overturn that assessment.

There is now a confirmed near-term event: the company's investor calendar lists a September 15 conference appearance. New company announcements also broaden the data-platform story, but neither an announced dataset goal nor a funding ceiling establishes recognised revenue. Tempus investor events, Tempus news releases.

Bullish and bearish views on Tempus AI, Inc.

The model's bull view on Tempus AI, Inc. (TEM), in brief: Operating revenue supports the story. Tempus's July 30 results reported second-quarter 2026 revenue of $382.5 million, up 22% year over year, including Data & Applications revenue of $93.2 million, up 28%. Those reported sales provide operating evidence beyond the August… The bear view: Clinical success leaves economics unresolved. Both cases follow in full.

Bull Case

• Operating revenue supports the story. Tempus's July 30 results reported second-quarter 2026 revenue of $382.5 million, up 22% year over year, including Data & Applications revenue of $93.2 million, up 28%. Those reported sales provide operating evidence beyond the August clinical headline. Second-quarter results.
• Management raised the financial hurdle. On July 30, Tempus raised full-year 2026 revenue guidance to $1.595–1.605 billion and projected approximately $65 million of adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA). These remain management forecasts; a subsequent revenue outlook below the published range would contradict this part of the case. Second-quarter results.
• Fresh projects extend platform scope. On September 9, Tempus announced up to $9.5 million in ARPA-H ADVOCATE funding for cardiology artificial intelligence. Its September 11 genome initiative announced a goal of making 100,000 disease-specific whole-genome sequences available alongside longitudinal clinical outcomes; that is a development objective, not a completed dataset or revenue result. Company announcements.

Bear Case

• Clinical success leaves economics unresolved. The September 5 published research identified no disclosed commercial supply contract linking Tempus's revenue to the August 19 Merck–Moderna readout. The clinical result alone therefore cannot establish the size or timing of a Tempus revenue contribution.
• Coverage has outlasted price strength. Benzinga reported Cantor Fitzgerald's $80 analyst target on September 2 and UBS's Neutral initiation with a $70 target on September 9. The September 11 market close of $59.01 was below the September 4 reference close of $64.62; the coverage did not coincide with recovery across those observations.
• The acquisition remains conditional. The July 20 transaction announcement described an approximately $1.5 billion enterprise value and an expected late-2026 or early-2027 closing, subject to shareholder and regulatory approvals. Termination or a formally delayed closing would undermine the proposed route to owning Personalis's MRD technology. Transaction announcement.

Setup & Price Structure

The September 11 adjusted daily close was $59.01. The supplied market record shows a three-month price increase of 23.4%, a 42.8% distance below the $103.25 trailing-year high, and a 14-period relative strength index (RSI) of 26.6 on that date. Those measurements show that the positive three-month change coexists with recent weakness; they do not establish a reversal.

The September 5 published dossier identified $58 as the pre-catalyst shelf. That existing research threshold remains unchanged, while the August 21 close of $72.69 defines price recovery for this thesis. The latest close remains above the boundary, but the supplied observations cannot establish whether any earlier weekly breach occurred.

Positioning evidence is limited to identifiable disclosures: Benzinga's September 2 report recorded ARK's $15.6 million of Tempus sales on September 1. That observation and the dated analyst coverage cluster do not measure market-wide crowding. No current moving-average distance, short-interest series or retail-flow measure is supplied; the sample is too small to support a broader positioning claim.

Catalyst Calendar (next 30 days)

As reviewed on September 13, the company event calendar supplies no additional confirmed event through October 13. The August 31 registration statement described in the September 5 dossier left the Personalis meeting date blank; no verified replacement date is available here. The earlier estimated merger milestones therefore remain unscheduled, and no estimated earnings date is presented as confirmed.

Elapsed catalysts

• 2026-09-15 — Morgan Stanley healthcare conference. Tempus lists a fireside chat at 8:30 a.m. Eastern time. The event provides an opportunity for dated disclosure about the merger or data commercialisation; an appearance without new terms, revenue information or a timetable would leave those questions unresolved. Company event calendar. (passed 5d ago)

What Would Change Our Mind

Loss of the published pre-catalyst shelf would end the recovery thesis: a weekly close below $58 is the price invalidation condition retained from the September 5 dossier. A daily close above the August 21 reference close of $72.69 before that breach would satisfy the defined price case. A rebound by itself would leave the commercial read-through unproven.

The operating assessment would strengthen with a named commercial agreement and disclosed economics connecting Tempus or Personalis to the therapy workflow identified after the August 19 readout. Conversely, termination of the July 20 merger agreement or a revenue outlook below the July 30 full-year range of $1.595–1.605 billion would break a substantive part of the company case even before price confirmation.

Correlation Notes

The August 19 Merck–Moderna trial result supplies an event connection to cancer vaccines, while the July 20 Personalis agreement supplies the proposed connection to MRD testing. Neither establishes a measured return correlation with Moderna, Merck or other diagnostic companies. No comparative return series is available in this record.

The September 11 price observations support treatment as a single-name setup. A group-led recovery would require contemporaneous evidence of broader participation; no such group move is established here.